Copyright
©The Author(s) 2016.
World J Hepatol. Dec 18, 2016; 8(35): 1541-1546
Published online Dec 18, 2016. doi: 10.4254/wjh.v8.i35.1541
Published online Dec 18, 2016. doi: 10.4254/wjh.v8.i35.1541
Figure 1 Proposed algorithm for deciding to continue or stop sorafenib in patients with hepatocellular carcinoma.
ce CT scan: Contrast-enhanced computed tomography scan; ce MRI: Contrast-enhanced magnetic resonance imaging; DC: Disease controlled; PD: Progressive disease; BSC: Best supportive care.
- Citation: Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol 2016; 8(35): 1541-1546
- URL: https://www.wjgnet.com/1948-5182/full/v8/i35/1541.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i35.1541